Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0507A, dorzolamide timolol · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| MK0507A, dorzolamide hydrochloride (+) timolol maleate | DRUG | - |
| Comparator: timolol maleate | DRUG | - |
| Duration of Treatment: Part 1) 6 wk timolol maleate run in | DRUG | - |
| Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds | DRUG | - |
Inclusion Criteria: * Patients with glaucoma or ocular hypertension Exclusion Criteria: * Other eye conditions * Poor vision * Recent eye surgery * Use of contact lenses * Nursing or pregnant women * Use of some other selected medications * Drug or alcohol abuse * Asthma * Slow heart beat * Aller...
Top 4 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 5 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
MK0507A is being developed for the treatment of glaucoma, a condition involving increased pressure inside the eye. It is a small molecule combination product in Phase 3 development. Merck & Company, Inc. is the developer, and the drug has also been studied in patients with ocular hypertension.
MK0507A is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor behind the clinical program for this glaucoma candidate, including the Phase 3 study that has been completed in patients with glaucoma and ocular hypertension.
MK0507A is in Phase 3 development. One Phase 3 trial has been completed, and no active trials are currently listed. The program has enrolled 330 patients in total, and the drug remains an investigational combination product for glaucoma rather than a marketed therapy.
Yes. MK0507A is also known as dorzolamide hydrochloride (+) timolol maleate, so searches for dorzolamide timolol refer to the same asset. It is a small molecule combination product developed by Merck for glaucoma, and it has completed a Phase 3 clinical trial in patients with glaucoma and ocular hypertension.
MK0507A has been studied in the Phase 3 trial NCT00108017, titled Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137). That trial is completed and enrolled 330 patients aged 18 years and older with glaucoma or ocular hypertension. It was randomized and double blind.
The Phase 3 trial NCT00108017 was a randomized, double-blind study that enrolled 330 patients with glaucoma or ocular hypertension. Participants were 18 years of age or older, and both sexes were eligible. The study has been completed, and it is the only trial of MK0507A listed for the program.